Skip to content
Open access

RNA-Binding Protein CSTF2 Drives Immune Evasion and Malignant Progression in Breast Cancer by Degrading THSD1 mRNA

Sep 2026 · Breast Cancer · Vol 18 · 0 citations · 36 references
Medicine

TL;DR

This study delineates the detailed molecular mechanisms by which the RBP CSTF2 exacerbates malignant progression in BC, offering fresh theoretical insights and potential targets for targeted immunotherapeutic strategies in BC.

Abstract

Objective Resistance to immunotherapy in breast cancer (BC) is intimately connected to the dynamic tumor immunoediting process. RNA-binding proteins (RBPs) are recognized as pivotal modulators of BC advancement. Cleavage stimulation factor 2 (CSTF2), a core factor involved in mRNA 3′-end maturation, shows significant overexpression in numerous cancers and is correlated with adverse clinical outcomes. However, the precise molecular mechanisms through which it drives malignancy by regulating immunoediting remain incompletely understood. Methods This study performed a systematic evaluation of CSTF2’s expression profile and prognostic significance in BC using data from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO). CSTF2 expression was modulated via knockdown and overexpression approaches to study core malignant traits, such as proliferative capacity and cell migration. The role of CSTF2 in immunoediting was examined through immune landscape analysis and flow cytometry. Results Integrated bioinformatics identified a regulatory pathway whereby CSTF2 induces transcriptional upregulation of the immune checkpoint molecule programmed death-ligand 1 (PD-L1) by promoting degradation of thrombospondin type-1 domain-containing protein 1 (THSD1) mRNA. The consequent increase in PD-L1 expression potently inhibits CD8⁺ T cell-mediated tumoricidal activity, thereby facilitating immune escape and collectively accelerating malignant progression in BC. Conclusion This study delineates the detailed molecular mechanisms by which the RBP CSTF2 exacerbates malignant progression, offering fresh theoretical insights and potential targets for targeted immunotherapeutic strategies in BC.

Read PDF

Similar papers

Open access Sep 2026

CSTF2 facilitates ATAD2 translation via m⁶A recognition to drive ER-positive breast cancer metabolic reprogramming and tumor progression

Breast cancer (BC) is the most common malignancy among women worldwide, accounting for 11.7% of female cancer cases. Cleavage stimulation factor subunit 2 ( CSTF2 ), a key RNA-binding protein, modulates tumor development by influencing N⁶-methyladenosine (m⁶A) modifications of mRNAs. This study aimed to clari...

Ying Liang, Miao Zhang, Dian-Bin Ning · 0 citations
Open access Aug 2026

HDAC2 restrains IGF2BP1-associated m6A dysregulation in cervical cancer immunotherapy resistance

Background Cervical cancer (CC) immunotherapy resistance remains a critical clinical challenge. Although immune checkpoint blockade shows efficacy in subsets of patients, the epigenetic and post-transcriptional mechanisms driving resistance are poorly understood. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF...

Qiuhong Deng, Zhi Wang, Ji-Ne Zhao et al. · 0 citations
Sep 2026

Targeting PPP1R14B overcomes immunotherapy resistance in prostate cancer by restoring CD8+ T-cell infiltration via the Nrf2/CX3CL1 axis.

PPP1R14B (PP1 regulatory inhibitor subunit 14B) was overexpressed in PCa and associated with poor prognosis, promoting PCa cell proliferation, suppressing apoptosis, and correlating with increased tumor purity but reduced CD8+ T-cell infiltration.

Jie Yang, Chuan Zhou, Wen-Bo Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.